Therapeutic targeting of prostate cancer

Cancer Biology and Therapy

Volumn 3, Issue 10, 2004, Pages 1028-1030

  Cress, Anne E ^a   Mohla, Suresh ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cell adhesion; Extracellular matrix; Genetic risk; Imaging; Prostate; Therapeutic targeting; Tumor migration

Indexed keywords

ANTIANDROGEN; ANTIESTROGEN; BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT;

ANAMNESIS; BIOPSY; CANCER CELL; CANCER CENTER; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER TISSUE; CELL ADHESION; CLINICAL FEATURE; CONCENTRATION (PARAMETERS); CONFERENCE PAPER; DIAGNOSTIC PROCEDURE; DRUG MECHANISM; EXTRACELLULAR MATRIX; GENOMICS; GLEASON SCORE; HUMAN; IMAGING; MATHEMATICAL MODEL; MOLECULAR BIOLOGY; NOMOGRAM; NONHUMAN; PHENOTYPE; PREDICTION; PREOPERATIVE PERIOD; PROSTATE CARCINOMA; PROSTATE EPITHELIUM; PROSTATECTOMY; PROTEOMICS; RADIODIAGNOSIS; STANDARDIZATION; STROMA; TOXICITY; TREATMENT OUTCOME; TREATMENT PLANNING; ANIMAL; DISEASE MODEL; GENE THERAPY; GENETICS; IMMUNOTHERAPY; MALE; PATHOLOGY; PROSTATE TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; GENE THERAPY; HUMANS; IMMUNOTHERAPY; MALE; PROSTATIC NEOPLASMS;

EID: 21244454368     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.3.10.1266     Document Type: Conference Paper

References (22)

1. Morris MJ, Scher HI, Shaffer DR. Optimizing targeted therapy and developing novel outcome measures for patients with advanced prostate cancer at Memorial Sloan-Kettering Cancer Center Prostate cancer: a dynamic illness with shifting targets. Crit Rev Oncol Hematol 2003; 46:521-31.
2. Greene KL, Meng MV, Elkin EP, Cooperberg MR, Pasta DJ, Kattan MW, et al. Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: Results from the Cancer of the Prostate Strategic Urological Research Endeavor (CAPSURE) Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. J Urol 2004; 171:2255-9.
3. Vanasupa BP, Miller TA, Schwartz BF. Diagnosis of prostate adenocarcinoma using transurethral resection of the prostate after multiple negative transrectal biopsies and persistently elevated prostate-specific antigen level. Urology 2000; 56:1056.
4. Nagle RB. Role of the extracellular matrix in prostate carcinogenesis. J Cell Biochem 2004; 91:36-40.
5. Udayakumar TS, Nagle RB, Bowden GT. Fibroblast growth factor-1 transcriptionally induces membrane type-1 matrix metalloproteinase expression in prostate carcinoma cell line. Prostate 2004; 58:66-75.
6. Koshikawa N, Schenk S, Moeckel G, Sharabi A, Miyazaki K, Gardner H, et al. Proteolytic processing of laminin-5 by MT1-MMP in tissues and its effects on epithelial cell morphology. Faseb J 2004; 18:364-6. Epub 2003; Dec 19.
7. Udayakumar TS, Chen ML, Bair EL, von Bredow DC, Cress AE, Nagle RB, Bowden GT. Membrane type-1-matrix metalloproteinase expressed by prostate carcinoma cells cleaves human laminin-5 β1 chain and induces cell migration. Cancer Res 2003; 63:2292-9.
8. Sikes RA, Nicholson BE, Koeneman KS, Edlund NM, Bissonette EA, Bradley MJ, et al. Cellular interactions in the tropism of prostate cancer to bone gene therapy for prostate cancer bone metastasis. Gene therapy targeting bone metastasis modulation of prostate cancer growth in bone microenvironments. Int J Cancer 2004; 110:497-503.
9. Marker PC, Donjacour AA, Dahiya R, Cunha GR. Hormonal, cellular, and molecular control of prostatic development. Dev Biol 2003; 253:165-174.
10. Schmelz M, Cress AE, Scott KM, Burger F, Cui H, Sallam K, et al. Different phenotypes in human prostate cancer: alpha6 or alpha3 integrin in cell-extracellular adhesion sites. Neoplasia 2002; 4:243-54.
11. Demetriou MC, Pennington ME, Nagle RB, Cress AE. Extracellular alpha 6 integrin cleavage by urokinase-type plasminogen activator in human prostate cancer. Exp Cell Res 2004; 294:550-8.
12. Demetriou MC, Cress AE. Integrin clipping: A novel adhesion switch? J Cellular Biochem 2004; 91:26-35.
13. Parsons JT. Focal adhesion kinase: the first ten years. J Cell Sci 2003; 116:1409-1416.
14. Nie D, Nemeth J, Qiao Y, Zacharek A, Li L, Hanna K, et al. Increased metastatic potential in human prostate carcinoma cells by overexpression of arachidonate 12-lipoxygenase. Clin Exp Metastasis 2003; 20:657-63.
15. Goel HL, Fornaro M, Moro L, Teider N, Rhim J, King M, Languino LR. Selectide modulation of type 1 insulin-like growth factor receptor signaling and functions by β1 integrins. J Cell Biol 2004; 166:3.
16. Tran NL, Adams DG, Vaillancourt RR, Heimark RL. Signal transduction from N-cadherin increases Bcl-2. Regulation of the phosphatidylinositol 3-kinase/Akt pathway by homophilic adhesion and actin cytoskeletal organization. J Biol Chem 2002; 277:32905-14. Epub 2002; Jul 02.
17. Thoreson MA, Reynolds AB. Altered expression of the catenin p120 in human cancer: implications for tumor progression. Differentiation 2002; 70:583-9.
18. Oshiro MM, Watts GS, Wozniak RJ, Junk DJ, Munoz-Rodriguez JL, Domann FE, et al. Mutant p53 and aberrant cytosine methylation cooperate to silence gene expression. Oncogene 2003; 22: 3624-34.
19. Martin DB, Gifford DR, Wright ME, Keller A, Yi E, Goodlett DR, et al. Quantitative proteomic analysis of proteins released by neoplastic prostate epithelium. Cancer Res 2004; 64:347-55.
20. Stuart RO, Wachsman W, Berry CC, Wang-Rodriguez J, Wasserman L, Klacansky I, et al. In silico dissection of cell-type-associated patterns of gene expression in prostate cancer. Proc Natl Acad Sci USA 2004; 101:615-20.
21. Gillies RJ. In vivo molecular imaging. J Cell Biochem Suppl 2002; 39:231-238.
22. Sato M, Johnson M, Zhang L, Zhang B, Le K, Gambhir SS, et al. Optimization of adenoviral vectors to direct highly amplified prostate-specific expression for imaging and gene therapy. Mol Ther 2003; 8:726-37.